Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After The Cliff: Fewer Patent Expiries Mean Less Savings From Generics

Executive Summary

A PwC report on medical cost trends projects that while US health care cost-growth has plateaued, several inflationary factors remain, including a reduction in big-ticket prescription drugs going off-patent. The trend began in 2016 and is expected to continue in 2018.

Advertisement

Related Content

Generic Manufacturers Try To Up Their Game As US Pressure Persists
Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says
Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard
Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel